Bienaime Jean Jacques's Form 4 filing
Ascendis Pharma A/S (ASND) · filed Jun 1, 2026
- Accession no.
- 0001610717-26-000177
- Filed
- Jun 1, 2026
- Trade date
- May 29, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $111.6K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Ordinary Shares | PPurchaseAcquired | +200 | $223.76 | +$44,752 | 600 | Direct | |
| May 29, 2026 | Ordinary Shares | PPurchaseAcquired | +200 | $222.30 | +$44,460 | 800 | Direct | |
| May 29, 2026 | Ordinary Shares | PPurchaseAcquired | +100 | $223.50 | +$22,350 | 900 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.